Sonja Leyrer

This inventor holds 27 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Viral Vaccine Development. Top assignees: Bavarian Nordic A/s, Venture Technologies Sdn Bhd, Emergent Product Development Gmbh. Active years: 2007-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sonja Leyrer. Retrieved from https://idiyas.com/inventor/sonja-leyrer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 7)

% Patents Active = 37.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 2.5

ph-index = 7

Forward Citations = 169(Granted Patents)

Location History:

München, DE (2007 - 2014)
Munich, DE (2008 - 2015)

Company Filing History:

Venture Technologies Sdn Bhd

patents

1 out of 1

Emergent Product Development Gmbh

patent

where one patent can have more than one assignee

Years Active: 2007-2015

Loading Chart...

Areas of Expertise:

HIV Fusion Proteins

Modified Vaccinia Virus

Recombinant Poxvirus

Viral Vaccine

Intergenic Regions

HIV Genes

Immune Response

DNA Sequences

Promoters

Subunit Vaccine

Flavivirus NS1

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9109233 - Recombinant poxvirus expressing homologous genes inserted (2015-08-18),

2. 8815501 - Flavivirus NS1 subunit vaccine (2014-08-26),

3. 8741653 - Single recombination system and methods of use (2014-06-03),

4. 8741308 - Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) (2014-06-03),

5. 8435543 - Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) (2013-05-07),

6. 8435535 - Fusion proteins of HIV regulatory/accessory proteins (2013-05-07),

7. 8414900 - Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) (2013-04-09),

8. 8389275 - Fusion proteins of HIV regulatory/accessory proteins (2013-03-05),

9. 8323661 - Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) (2012-12-04),

10. 8309326 - Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) (2012-11-13),

11. 8309098 - Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) (2012-11-13),

12. 8288125 - Intergenic regions as insertion sites in the genome of modified vaccinia virus Ankara (MVA) (2012-10-16),

13. 8198088 - Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs) (2012-06-12),

14. 8197822 - Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs) (2012-06-12),

15. 8147839 - Fusion proteins of HIV regulatory/accessory proteins (2012-04-03),

Title: The Innovative Contributions of Sonja Leyrer in Biotechnology

Introduction: Sonja Leyrer is a prominent inventor based in Munich, Germany, known for her significant contributions to the field of biotechnology. With an impressive portfolio of 27 patents, she has made remarkable advancements that focus on innovative vaccine technologies and recombinant virus applications.

Latest Patents: Among her most notable patents is the "Recombinant poxvirus expressing homologous genes inserted." This invention involves a recombinant poxvirus vector designed to express multiple homologous foreign sequences derived from different variants of a microorganism, with a homology of 50% or above. This innovative approach enables the development of vaccines and medicaments aimed at inducing immune responses in living organisms, including humans. Another key patent is the "Flavivirus NS1 subunit vaccine," which pertains to NS1 proteins or their parts from Flaviviruses, particularly Dengue viruses. This invention offers solutions for effective vaccination against various Dengue virus serotypes, showcasing Leyrer’s commitment to enhancing global health through her research.

Career Highlights: Sonja Leyrer has made pivotal contributions during her tenure at leading biotechnology firms, including Bavarian Nordic A/S and Venture Technologies Sdn Bhd. Her work in these organizations has helped pioneer cutting-edge solutions in vaccine development and molecular biology.

Collaborations: Throughout her career, Leyrer has collaborated with distinguished professionals in her field, including Paul Michael Howley and Eva Felder. These partnerships not only reflect her ability to work within teams but also contribute to the impactful nature of her research.

Conclusion: Sonja Leyrer continues to be a driving force in the realm of biotechnology with her inventive work and numerous patents. Her advancements in recombinant virus applications and vaccine technologies are crucial in addressing public health challenges and enhancing disease prevention strategies. The impact of her innovative contributions will undoubtedly resonate within the scientific community and beyond as she continues her journey as an influential inventor in this vital field.

Profile summary based on public USPTO records.